OncLive TV

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the role of melflufen in the treatment of patients with myeloma.

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses mechanisms of resistance in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses rare drivers in non–small cell lung cancer (NSCLC).

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses common adverse events associated with radiation therapy in the treatment of patients with lung cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the management of TKI-associated adverse events in kidney cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses a study looking at real-world benefit of BTK inhibitors versus what is seen in clinical trials for patients with mantle cell lymphoma.

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the treatment of patients with newly diagnosed myeloma.

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.